Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
暂无分享,去创建一个
[1] K. Brøsen,et al. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.
[2] A. Boobis,et al. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. , 1989, Biochemical pharmacology.
[3] K. Midha,et al. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.
[4] R. Dahlqvist,et al. Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.
[5] K. Midha,et al. Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. , 1987, Journal of pharmaceutical sciences.
[6] C. Kozak,et al. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. , 1987, DNA.
[7] K. Midha,et al. Methoxyphenamine O-demethylase and 5-hydroxylase: a GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine. , 1987, Pharmacology & therapeutics.
[8] A. Boobis,et al. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. , 1986, Biochemical pharmacology.
[9] T. Yoshida,et al. Studies on the mechanism of interaction between methamphetamine and quinine in rats. , 1986, Journal of Pharmacobio-Dynamics.
[10] G McKay,et al. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.
[11] T. Henthorn,et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.
[12] W. Kalow,et al. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[13] K. Midha,et al. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. , 1985, Canadian journal of physiology and pharmacology.
[14] F. Guengerich,et al. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. , 1984, Biochemistry.
[15] W. Kalow,et al. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.
[16] K. Midha,et al. Identification of new secondary metabolites of methoxyphenamine in man. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.
[17] J. Idle,et al. Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains , 1981, The Journal of pharmacy and pharmacology.